Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Contraceptive Technology Update

RSS  

Articles

  • Injectable update: Subcutaneous form of Depo-Provera is approved

    The drug, approved by the Food and Drug Administration (FDA) in December, should be available on retail pharmacy shelves in mid-May, says An Phan, Pfizer corporate spokeswoman. Pricing has not been set yet on the drug, she adds.
  • Hormonal-based male contraceptive moves ahead

    Clinical trials for a male contraceptive that is a combination of progesterone and testosterone are expected to begin this year.
  • African American women hit hard by HIV/AIDS

    African American women are far more likely to be infected with HIV than are white women and Hispanic women, a problem that has been growing, according to recent reports by the Centers for Disease Control and Prevention (CDC).
  • Clinical trials begin for spray-on contraceptive

    A spray-on birth control method for women recently has entered a Phase I clinical trial in which six women in Sydney, Australia, are using the new product as part of a study to determine whether the transdermal contraceptive can be used in spray formulation effectively.
  • Male contraceptives are gaining momentum

    The first male contraceptives to make it to the market likely will be hormonal-based birth control, similar to what has worked well for female contraceptives for the past four decades. However, there are serious difficulties with hormonal contraceptives for men, so the possibilities that are beginning to excite researchers working in the contraceptive field are the nonhormonal methods.
  • Be prepared to counsel on use of DMPA and bone health issues

    Its time to update your counseling on the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer; New York City). The Food and Drug Administration (FDA) has added a black box warning to the drugs labeling to highlight that prolonged use may result in the loss of bone mineral density (BMD).
  • Letter to the Editor

    I have been a subscriber to Contraceptive Technology Update for many years and rarely take issue with the content. I must, however, register my total surprise and dismay at your 25 Events to Know in Reproductive Health that appeared in the January 2005 issue.
  • STD Quarterly: Task force: Screen all pregnant women for HIV

    Consider these facts: Women are the fastest-growing group in the United States with newly diagnosed HIV, and last year, an estimated 6,000-7,000 women with HIV gave birth.
  • Check choices for women with epilepsy

    In reviewing the chart for your next patient, you note that she is a 28-year-old woman with epilepsy. What information do you need to provide her when it comes to contraceptive choices? Many family planning clinicians encounter this scenario. Epilepsy is one of the most common chronic health conditions affecting reproductive-age women.
  • Certain types of breast disease may signal risk

    New evidence indicates that women with benign breast disease have a higher risk for breast cancer, and that certain types of breast disease may predict the near-term development of breast cancer.